In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...
PCI for coronary chronic total occlusion significantly improves angina symptom scores compared with placebo in patients with stable angina.
(BPT) - For the 11 million Americans living with angina, chronic chest pain caused by a lack of blood flow to the heart muscle can touch every aspect of daily life. 1 From relationships to careers and ...
SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ...
Most patients with coronary artery disease (CAD) and chronic stable angina will obtain complete relief of symptoms with percutaneous coronary intervention (PCI). However, some chronic angina patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results